16:09:27 Europe / Stockholm

Svenska | English

Gubra

Prenumeration

Kalender

2024-08-23	Kvartalsrapport 2024-Q2
2024-04-04	Ordinarie utdelning GUBRA 0.00 DKK
2024-04-03	Årsstämma 2024
2024-02-28	Bokslutskommuniké 2023
2023-11-01	Extra Bolagsstämma 2023
2023-08-25	Kvartalsrapport 2023-Q2

Beskrivning

Land	Danmark
Lista	Mid Cap Copenhagen
Sektor	Hälsovård
Industri	Medicinteknik

Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.

Filter

År

Typ

Språk

Rensa

2024-04-17 07:30:00 Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss +8,96% | 43,1 MDKK

2024-04-04 12:32:00 RESOLUTIONS OF GUBRA A/S' ANNUAL GENERAL MEETING 2024 +0,67% | 51,3 MDKK

2024-04-03 21:45:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares +0,67% | 51,3 MDKK

2024-04-03 21:35:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares +0,67% | 51,3 MDKK

2024-03-27 14:45:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares +11,92% | 47,4 MDKK

2024-03-26 22:45:00 Major shareholder announcement: The Capital Group Companies Inc. +11,92% | 47,4 MDKK

2024-03-25 11:29:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares -6,33% | 196 MDKK

2024-03-25 09:56:00 Major shareholder announcement -6,33% | 196 MDKK

2024-03-06 09:00:00 NOTICE TO CONVENE ANNUAL GENERAL MEETING 2024 +0,45% | 17,6 MDKK

2024-03-04 21:41:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares +4,76% | 26,2 MDKK

2024-02-28 07:30:00 Annual Report 2023 – Revenue in the CRO business growing by 29% to record high level +8,82% | 8,55 MDKK

2024-01-26 13:33:00 Gubra concludes the research agreement with UK Biotech -0,82% | 0,15 MDKK

2023-12-13 17:19:00 Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration +4,84% | 7,09 MDKK

2023-11-29 12:51:00 Gubra announces first subject dosed in Phase 1 clinical trial of amylin agonist (GUBamy) for the treatment of obesity +2,11% | 0,02 MDKK

2023-11-08 07:30:00 Trading statement Q3-2023: Continued strong performance -0,62% | 0,49 MDKK

2023-11-01 11:01:00 Gubra strengthens Board of Directors -0,02% | 0,07 MDKK

2023-11-01 10:40:00 Gubra - Extraordinary general meeting -0,02% | 0,07 MDKK

2023-10-26 12:35:00 Gubra enters into a Market Maker Agreement +7,19% | 0,26 MDKK

2023-10-26 08:01:00 Gubra raises financial guidance for full-year 2023 +7,19% | 0,26 MDKK

2023-10-24 07:30:00 Gubra opens its first US office in Boston -0,89% | 0,04 MDKK

2023-10-09 14:00:00 NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING -0,04% | 0,01 MDKK

2023-09-06 09:58:00 Gubra submits clinical trial application (CTA) for first-in-human amylin trial +4,82% | 1,06 MDKK

2023-09-01 11:41:00 Completion of share buy-back programme +1,77% | 0,54 MDKK

2023-08-28 08:15:00 Gubra resumes its share buy-back programme to hedge incentive scheme obligations -1,35% | 3,86 MDKK

2023-08-25 07:30:00 Interim report H1-2023: Strong performance and ahead of expectations -1,83% | 0,26 MDKK

2023-08-23 16:44:00 Gubra announces termination of collaboration with Bayer -2,80% | 13,5 MDKK

2023-08-21 15:29:00 Gubra A/S announces signing of collaboration agreement with Hemab ApS +5,88% | 0,36 MDKK

2023-08-15 13:19:00 Gubra raises financial guidance for full-year 2023 +7,05% | 0,51 MDKK

2023-07-28 19:41:00 Information on share buy-back programme +1,66% | 0,06 MDKK

2023-06-30 08:00:00 Gubra launches share buy-back programme to hedge incentive scheme obligations +2,31% | 0,18 MDKK

2023-06-29 07:00:00 Gubra acquires research service provider MiniGut ApS +4,40% | 0,24 MDKK

2023-06-09 07:30:00 Gubra announces updates to its pipeline. Internally developed brain-accessible orexin peptides for the treatment of narcolepsy, now ready for partnering +6,80% | 3,55 MDKK

2023-06-02 11:50:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares +2,01% | 0,34 MDKK

2023-06-02 11:41:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares +2,01% | 0,34 MDKK

2023-05-24 17:11:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares +1,09% | 0,02 MDKK

2023-05-24 17:08:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares +1,09% | 0,02 MDKK

2023-05-17 07:30:00 Phase 1 trial results from a novel long acting NPY2-receptor agonist in partnership between Gubra A/S and Boehringer Ingelheim presented today at the European Congress on Obesity, ECO 2023 +3,09% | 6,25 MDKK

2023-05-11 07:30:00 Gubra posts 19% CRO revenue growth in Q1 2023. Full-year 2023 outlook maintained. +2,67% | 0,40 MDKK

2023-05-09 13:41:00 Invitation to the presentation of Gubra’s Q1-2023 results -4,01% | 0,45 MDKK

2023-05-03 15:59:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares -0,56% | 0,07 MDKK

2023-05-03 15:51:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares -0,56% | 0,07 MDKK

2023-04-28 18:25:00 Partial exercise of the overallotment option in connection with the initial public offering of Gubra increasing total offering size to 4,913,521 shares 0,00% | 0,24 MDKK

2023-04-28 18:17:00 Gubra announces the end of the stabilisation period 0,00% | 0,24 MDKK

2023-04-12 17:28:00 Stabilisation measures taken 0,00% | 1,25 MDKK

2023-04-06 16:33:00 Major shareholder announcement +0,91% | 9,32 MDKK

2023-04-03 08:44:00 Completion of the offering and registration of capital increase in Gubra A/S -0,23%

2023-04-03 07:26:00 No termination or withdrawal of Gubra A/S' initial public offering -0,23%

2023-03-30 09:05:00 Major shareholder announcement

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Gubra

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden